Abstract: Background. We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carcinoma (HNSCC).
Head and neck squamous cell carcinomas (HNSCCs) represent approximately 2.4% of all cancers in the United States, where they were projected to account for 35,720 new diagnoses and 7600 deaths in 2009. 1 Advanced cancer stage at diagnosis and aggressive tumor biology contribute to the observed poor prognosis in newly diagnosed patients, whose 5-year survival rates range from 10% to 40%. 2 Thus, new treatment modalities are clearly needed to more effectively treat these malignancies.
Targeted molecular therapy is a promising new development in treating human cancers. 3 Unlike standard cytotoxic therapies, which generally lack specificity for tumor cells, the targeted molecular approach exploits known molecular changes in neoplastic cells. Potential biological targets for HNSCC are the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptor 2 (VEGFR-2). EGFR, a member of the receptor tyrosine kinase superfamily of transmembrane receptor proteins, is bound and activated by its ligands, which include epidermal growth factor (EGF) and transforming growth factor-a. The EGFR tyrosine kinase domain phosphorylates several second messenger molecules, providing signals that enhance cell survival, and increase cell proliferation. 4 Targeted inhibition of the overexpressed EGFR in neoplastic cells can, therefore, hinder cell proliferation and survival, making this an attractive target for molecular therapy. VEGFR mediates normal vascular development and physiological angiogenesis. However, the VEGF and VEGFR overexpression common in HNSCC facilitates tumor angiogenesis, allowing the neoplastic tumor to grow. 5 EGFR overexpression has been reported in 34% to 80% of cases of HNSCCs and correlates with shortened disease-free survival in patients with HNSCC. Increased VEGF and VEGFR expression have also been observed in aggressive subsets of these HNSCCs.
To evaluate the potential efficacy of targeting both EGFR and VEGFR signaling in HNSCC treatment, we tested vandetanib (AstraZeneca), an orally bioavailable small-molecule tyrosine kinase inhibitor that selectively targets both EGFR and VEGFR-2 tyrosine kinases. 9 We investigated the ability of vandetanib to inhibit EGFR and VEGFR-2 signaling and initiate an antiproliferative effect in vitro. We then examined its antitumorigenic and antiangiogenic capabilities in vivo, alone and in combination with the cytotoxic agent paclitaxel (Bristol-Myers). We hypothesized that vandetanib would inhibit cell proliferation in vitro, inhibit tumor growth and angiogenesis in vivo, and interact with paclitaxel in vivo to reduce tumor volume to a greater extent than vandetanib alone. 10 
MATERIALS AND METHODS
Animals and Maintenance. Eight-week-old to 12-week-old male athymic nude mice were purchased from the National Cancer Institute (Bethesda, MD). The mice were kept in a specific pathogen-free facility and were fed irradiated mouse chow and autoclaved, reverse osmosis-treated water. The facility was approved by the American Association for the Accreditation of Laboratory Animal Care and met all current regulations and standards of the U.S. Department of Agriculture, U.S. Department of Health and Human Services, and the National Institutes of Health. Animal procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee of The University of Texas M. D. Anderson Cancer Center.
Cell Lines. Two human HNSCC cell lines were used in the study. The FaDu line was purchased from the American Type Culture Collection (Manassas, VA). This cell line was established in 1968 from a punch biopsy of a hypopharyngeal carcinoma. The SCC61 line was obtained from Dr. Alissa Weaver of Vanderbilt University (Nashville, TN). This cell line was isolated from tongue squamous cell carcinoma (SCC) tumors. 11 FaDu cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine, sodium pyruvate, nonessential amino acids, and a 2-fold vitamin solution (Life Technologies, Grand Island, NY). SCC61 cells were maintained in DMEM supplemented with 20% FBS and 0.4 lg/mL hydrocortisone. Adherent monolayer cultures were maintained on plastic plates and incubated at 37 C in 5% carbon dioxide and 95% air. The cultures were free of mycoplasma species and were maintained for no longer than 12 weeks after recovery from frozen stocks.
Reagents. Vandetanib (Zactima, ZD6474) was provided by AstraZeneca Pharmaceuticals (Macclesfield, Cheshire, UK). For in vivo testing, vandetanib was dissolved in phosphate-buffered saline (PBS) containing 1% Tween 80. For in vitro testing, stock solutions of vandetanib were prepared in dimethylsulfoxide (Sigma-Aldrich Corp, St. Louis, MO) and diluted with culture medium. Paclitaxel (Taxol/Bristol-Myers Squibb, Princeton, NJ) was diluted in PBS to a 1 mg/ mL final concentration. Propidium iodide (PI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were both purchased from SigmaAldrich Corp (St. Louis, MO). Stock solutions were prepared by dissolving either 0.5 mg of PI or 2 mg of MTT in 1 mL of PBS. Each solution was then filtered to remove particles, protected from light, stored at 4 C, and used within 1 month.
The primary antibodies for immunohistochemical analysis were purchased as follows: rat monoclonal anti-mouse CD31 (platelet-endothelial cell adhesion molecule 1; BD Pharmingen, San Diego, CA). The secondary antibodies were used as follows: peroxidaseconjugated goat anti-rat immunoglobulin G1 (Jackson Research Laboratories, West Grove, PA); and Alexa Fluor 594-conjugated goat anti-rat immunoglobulin G.
Cell Proliferation Assay. The antiproliferative ability of vandetanib against HNSCC cells in vitro was determined using an MTT assay, as previously described. 12 Briefly, FaDu and SCC61 were plated in 96-well plates at 5000 cells per well in medium with 10% FBS and 20% FBS, respectively. After a 24-hour attachment period, the cells were incubated for 72 hours in various concentrations of vandetanib (0.3-15 lM) or with dimethylsulfoxide alone as a control. Cells were then incubated for 3 hours in medium containing 2% FBS and 0.25 mg/mL MTT, after which the cells were lysed in 100 lL dimethylsulfoxide to release the formazan. The conversion of MTT to formazan was quantified with an EL-808 96-well plate reader (BioTek Instruments, Winooski, VT) set at an absorbance of 570 nm. The concentration of vandetanib giving 50% growth inhibition (GI50) for each cell line was calculated using GraphPad Prism 5.01 (GraphPad Software, San Diego, CA). The experiment was repeated at least twice. The vandetanib GI50 was the average of the values from each MTT assay.
Flow Cytometry for Apoptosis. FaDu and SCC61 cells (2 Â 10 5 per well) were plated in 6-well plates (Costar, Cambridge, MA) in 2 mL medium containing 2% FBS, incubated for 24 hours, and then treated with various concentrations (2-5 lM) of vandetanib. Afterward, both adherent and detached cells were harvested, washed with PBS, and resuspended in Nicoletti buffer (50 lg/mL PI; 0.1% sodium citrate; 0.1% Triton X-100; and 1 mg/mL RNAse in PBS). Using the sub-G 0 /G 1 fraction, we calculated the percentage of apoptotic cells by gating the hypodiploid region on the DNA content histogram with the Lysis program (Becton Dickinson, Franklin Lakes, NJ). 13 
Western Blotting of Epidermal Growth Factor
Receptor Tyrosine Kinase Inhibition by Vandetanib. FaDu and SCC61 cells were plated in 6-well plates at 1.5 Â 10 5 cells per well and incubated in medium with 10% FBS and 20% FBS, respectively, overnight. The next day, the cells were washed with PBS and incubated in serum-free medium for 24 hours. Cells were then treated for 90 minutes with 0 to 10 lM vandetanib in dimethylsulfoxide. Next, EGF (50 ng/mL) was added for 15 minutes, after which the cells were washed in chilled (4 C) PBS and the plates were kept on ice. Total cell lysates were obtained and subjected to Western blot analysis, as previously described. 12 The membranes were blocked for 1 hour at room temperature with 5% bovine serum albumin in 0.1% Tween 20 in tris-buffered saline and incubated overnight at 4 C in anti-EGFR (Upstate Biotechnology, Lake Placid, NY; 1:500), anti-phospho-EGFR (Cell Signaling, Beverly, MA; 1:500), anti-Akt (Cell Signaling; 1:1000), anti-phospho-Akt (Cell Signaling; 1:1000), anti-mitogen-activated protein kinase (MAPK; Cell Signaling; 1:1000) or anti-phospho-MAPK (Cell Signaling; 1:1000) in the membrane-blocking solution described above. Next, the membranes were washed with Tween 20 in tris-buffered saline and incubated for 1 hour at room temperature in horseradish peroxidase-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) to detect EGFR and phospho-EGFR or species-appropriate fluorescently conjugated (goat anti-rabbit IRDye 800 and goat anti-mouse IRDye 800) for another protein. Membranes were then analyzed using the SuperSignal West chemiluminescent system (Pierce Biotechnology, Rockford, IL) and an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE), and where relevant, signal intensity was determined using Odyssey software (LI-COR Biosciences). To verify equal loading of proteins, membranes were stripped and reprobed with anti-b-actin (1:5000).
Orthotopic Nude Mouse Model of Head and Neck
Squamous Cell Carcinoma. FaDu and SCC61 cells were harvested from subconfluent cultures by trypsinization and washed with PBS. An orthotopic nude mouse model of an oral tongue tumor model was established by injecting FaDu (2 Â 10 5 ) or SCC61 (1.5 Â 10 5 ) cells suspended in 30 lL serum-free DMEM into the mouse tongue, as described previously. 14 Fourteen to 16 days after the cells were injected, the mice were randomly assigned to 1 of 4 groups (7-9 mice per group): control group, paclitaxel group, vandetanib group, or combination vandetanib þ paclitaxel treatment group. Drug regimens were administered as follows 15 : the control group was given 200 lL of 1% Tween 80 by oral gavage once daily and 200 lL PBS intraperitoneally once weekly; the paclitaxel group was given 200 lL 1% Tween 80 by oral gavage once daily and 200 lg of paclitaxel (in 200 lL) intraperitoneally once weekly; the vandetanib group was given vandetanib by oral gavage at 50 mg/kg once daily and 200 lL of PBS intraperitoneally once weekly; and the combination group was given vandetanib by oral gavage at 50 mg/kg once daily and 200 lg of paclitaxel intraperitoneally once weekly. The mice were examined twice a week for tumor size and weight loss. Tongue tumor size was measured with microcalipers. Tumor volume was calculated as (A)(B 2 )p/6, in which A is the longest dimension of the tumor and B is the dimension of the tumor perpendicular to A. Mice were euthanized by CO 2 asphyxiation when they had lost more than 20% of their preinjection body weight or at 28 days posttreatment, whichever came first. Half of the tumors were fixed in formalin and embedded in paraffin for immunohistochemical and hematoxylin-eosin staining; the other half were embedded in optimal cutting temperature compound (Miles, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at -80 C. The cervical lymph nodes were also embedded in paraffin, sectioned, stained with hematoxylin-eosin, and evaluated for metastases.
Immunohistochemical Analysis and Immunofluorescence Double Staining Analysis for CD31/Terminal
Deoxynucleotidyl Transferase-Mediated Deoxyuridine Triphosphate Nick-End Labeling. Frozen tissues, prepared as described above, were used for immunohistochemical-immunofluorescent analysis. Slides were prepared as previously described. 12 Immunostaining for CD31/PECAM-1 (BD Pharmingen; 1:400) was done using the methods indicated previously. 12 Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay was done using DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) as follows. Samples were fixed with 4% paraformaldehyde for 10 minutes, washed twice with PBS for 5 minutes, and then incubated with 0.2% Triton X-100 for 15 minutes. After two 5-minute washes with PBS, the samples were incubated with equilibration buffer for 10 minutes. At that time, the equilibration buffer was drained, and reaction buffer (44 lL equilibration buffer, 5 lL nucleotide mix, and 1 lL TDT) was added to the samples, the samples were then incubated in a humid atmosphere at 37 C for 1 hour, avoiding light exposure. The reaction was terminated by immersing the samples in 2 Â standard saline citrate for 15 minutes. Samples were then washed with PBS to remove unincorporated fluorescein-dUTP. For CD31-TUNEL double staining, after being fixed with acetone, the samples were washed with PBS, incubated with protein-blocking solution containing 5% normal horse serum and 1% normal goat serum in PBS for 20 minutes, and then incubated in a 1:400 dilution of anti-CD31/ PECAM-1 antibody (BD Pharmingen) for 1 hour. After being washed with PBS, the slide samples were incubated in a 1:600 dilution of a secondary antibody conjugated with Alexa Fluor 594 (Molecular Probes) for 1 hour, avoiding light exposure. The samples were sequentially stained in the TUNEL assay, creating the CD31-TUNEL double staining.
Immunofluorescence microscopy was done using a Leica DMLA microscope (Leica Microsystems, Bannockburn, IL) equipped with a 100-W HBO mercury bulb and filter sets (Chroma, Brattleboro, VT) to individually select red and blue fluorescent images. Images were captured using a cooled charge-coupled device Hamamatsu C5810 camera (Hamamatsu Corp, Bridgewater, NJ) and ImagePro Plus 6.0 software (Media Cybernetics, Silver Spring, MD). Photomontages were prepared using Adobe Photoshop software version 10.0.1 (Adobe Systems, San Jose, CA).
Quantification of Microvessel Density and Apoptotic
Endothelial Cells. For the quantification analysis, 3 slides were prepared for each treatment group. The percentage of stained cells among the total number of cells in each field and the average proportion of stained cells in each group were calculated and compared. To quantify TUNEL expression, we counted the cells positively stained in 8 random 0.04-mm 2 fields at Â200 magnification per slide. To quantify microvessel density (MVD), we identified areas containing high numbers of tumor-associated blood vessels at Â100 magnification. Vessels that had stained completely with anti-CD31 antibody were counted in 8 random 0.04-mm 2 fields at Â200 magnification. The number of apoptotic endothelial cells was calculated as the average of the ratio of apoptotic endothelial cells to the total number of endothelial cells in 8 random 0.04-mm 2 fields at Â200 magnification. Specimens from the combination group (vandetanib þ paclitaxel) were quantified in 8 random 0.04-mm 2 fields at Â200 magnification.
Statistical Analysis. Tumor volumes from the control group were compared with those from the 3 treatment groups using the 2-tailed t tests. Survival was analyzed by the Kaplan-Meier method and compared with log-rank tests. Fisher exact test was used to analyze associations between treatment groups and incidence of cervical lymph node metastases. Quantitative data related to the immunohistochemical expression of CD31 and CD31-TUNEL was compared with 2-tailed t tests. Furthermore, a 2-way analysis of variance was used to test for the effects of vandetanib and paclitaxel as single agents and for interaction between the compounds, as positive interaction represents drug synergy. Analysis was performed with GraphPad Prism version 5.01 (GraphPad Software).
For all comparisons, p < .05 was considered statistically significant. Figure 4 shows that the mean SCC61 tumor volumes of mice in the vandetanib group and the vandetanib and paclitaxel combination group were significantly lower than those of mice in the control group (p ¼ .0310 and p ¼ .0036, respectively) on day 21 of treatment. The mean tumor volume of mice in the paclitaxel group was also lower than that of mice in the control group; however, the difference was not statistically significant (p ¼ .4509).
These antitumor effects of treatment with vandetanib and/or paclitaxel were also observed in the FaDu orthotopic model (Figure 4) . The mean tumor volume was significantly lower in the combinationtreated group than in the control group at all time points (p ¼ .0406); however, the differences between the control group and the paclitaxel group or vandetanib-only group were not statistically significant (p ¼ .8188 and p ¼ .3056, respectively). Vandetanib seemed well-tolerated with no evidence of treatmentrelated weight loss. Cell Carcinoma. We also analyzed the effect of treatment on survival in an orthotopic mouse model of HNSCC. When tumors were palpable at day 14 to 16 after injection, the animals were randomized to groups that received vandetanib, paclitaxel, combined vandetanib and paclitaxel, or drug vehicle. Mice were euthanized when they had lost more than 20% of their initial body weight or at the end of the study (after 28 days of treatment). All of the FaDu control mice in the survival study were euthanized by day 27 after cell inoculation. The median survival periods for the control, paclitaxel, vandetanib, and combination groups in the FaDu mice were 27, 34, 39, and 44 days, respectively. FaDu mice treated with vandetanib and the vandetanib and paclitaxel combination survived longer than control mice (p ¼ .0019, p ¼ .0004, log-rank test, respectively). All SCC61 mice treated with vandetanib and the vandetanib and paclitaxel combination survived until the end of the study (p < .0001, p < .0001 vs control, log-rank test, respectively). The median survival periods for the control and paclitaxel-treated, vandetanib-treated, and combination-treated SCC61 mice were 26, 27, 42, and 42 days, respectively ( Figure 5 ). In the groups of animals with the FaDu tumors, which have metastatic potential to the cervical lymph nodes, superficial neck lymph nodes were harvested and examined histologically to determine the impact of treatment on cervical lymph node metastases. As shown in Table 1 , cervical lymph node metastases were detected in 66.7% of control mice, 77.8% of paclitaxel-treated mice, 33.3% of vandetanib-treated mice, and 20% of combination-treated mice. Although the difference between control group and treatment group did not reach statistical significance, both the vandetanib group and the combination group had a much lower incidence of cervical lymph node metastases. In the groups of animals with SCC61 tumor, only 22.2% of control mice and 12.5% of paclitaxel-treated mice showed cervical lymph node metastases, whereas no cervical lymph node metastasis was found in the vandetanib group and the combination group. The difference between the control group and each treatment group was not statistically significant. FaDu and SCC61 cells were injected into the tongues of nude mice. After tumor nodules developed, mice were treated by oral gavage with vandetanib at 50 mg/kg daily, intraperitoneally with paclitaxel at 200 lg, with a combination of vandetanib and paclitaxel at the same doses, or with vehicle alone (control group). Subject animals were euthanized when they had lost more than 20% of their initial body weight or after 28 days of treatment. Survival was analyzed by the Kaplan-Meier method and compared with log-rank tests. Figure 6B ). The TUNEL assay showed that tumor cells in mice treated with vandetanib, alone or in combination with paclitaxel, underwent apoptosis and did so to a greater extent than tumor cells from the control group (control, 4.32% AE 0.58%; paclitaxel, 12.46 AE 2.33, p < .01; vandetanib, 14.95 AE 1.47, p < .001 vs control; and vandetanib þ paclitaxel, 27.31 AE 3.38, p < .0001 vs control; Figure 6C ). Finally, double staining for CD31-TUNEL showed that the percentage of apoptotic endothelial cells was significantly higher in the tumors of mice treated with vandetanib and the vandetanib and paclitaxel combination than in tumors of mice in the control group (control, 0%; paclitaxel, 1.24 AE 0.52, p < .05 vs control; vandetanib, 13.45 AE 3.20, p < .001 vs control; and vandetanib þ paclitaxel, 17.28 AE 4.17, p < .001 vs control; Figure  6D ). These immunohistochemical results support the notion that vandetanib decreases MVD associated with increased apoptosis of tumor-associated endothelial cells in vivo.
DISCUSSION
In this study, we demonstrated that vandetanib effectively inhibits ligand-dependent phosphorylation of EGFR and its downstream mediators, Akt and MAPK. Vandetanib treatment also leads to inhibition of cell proliferation in vitro and in vivo, induction of tumor and endothelial cell apoptosis in vivo (alone or in combination with paclitaxel), a decrease in tumor size in vivo, and prolonged survival in an orthotopic nude mouse model. These biologic findings underscore the potential effect of this drug in future clinical trials for patients with HNSCC.
Several studies have reported overexpression of EGFR, a tyrosine kinase receptor that mediates several cellular functions associated with tumor progression, including proliferation, inhibition of apoptosis, and invasion. 16, 17 The 2 EGFR-targeting strategies with the best clinical outcomes are the small-molecule tyrosine kinase inhibitors and the anti-EGFR monoclonal antibodies. The efficacy of tyrosine kinase inhibitors (gefitinib and erlotinib) for recurrent and metastatic HNSCC have been studied in phase III clinical trials. 18 The most widely studied anti-EGFR monoclonal antibody is cetuximab, a human-murine chimeric immunoglobulin. Cetuximab was shown to improve survival in combination with radiotherapy in locally advanced HNSCC and improve response rates in recurrent or metastatic disease when used with cytotoxic chemotherapy agents. 19 Other monoclonal antibodies in early clinical trials for HNSCC include panitumumab and h-R3. 20 Tumor growth depends on an adequate vascular supply, which is mediated by angiogenic growth factors. The most potent angiogenic factor specific to endothelial cells is VEGF. 21 HNSCC growth has been shown to be associated with the presence of VEGF and upregulation of the VEGF-R in tumor endothelial cells. 22 The most developed monoclonal antibody against VEGF at this time is bevacizumab, which has shown synergistic effects with chemotherapy. This combination has already been approved as the firstline treatment for colorectal cancer, non-small cell lung cancer, and breast cancer. Conceptually, despite the success of bevacizumab through highly selective inhibition of VEGF-A-dependent signaling, achieving therapeutic goals through multi-target therapies is a more attractive approach for heterogenous tumors. Targeting 2 pathways simultaneously (ie, inhibiting EGFR and VEGFR signaling) may also limit the development of acquired drug resistance. Studies in preclinical HNSCC models have shown that inhibiting both EGFR and VEGFR signaling can effectively inhibit tumor growth and induce apoptosis. 12 Therefore, the strategy of combining antiangiogenic and chemotherapeutic agents can be applied to a broad range of tumor types, including HNSCC. 10 In the present study, we examined whether vandetanib would inhibit the growth of HNSCC cells injected into the tongues of nude mice and improve their survival. Because tyrosine kinase inhibition can enhance the antitumor activity of cytotoxic drugs, 23, 24 we also investigated the combined effects of vandetanib and paclitaxel on HNSCC. Paclitaxel inhibits cellular division by hyperstabilizing microtubule growth and is a commonly used chemotherapeutic agent for a variety of cancers, including HNSCC. 25 Paclitaxel has also been shown to induce apoptosis in a human HNSCC cell line in a dose-and time-dependent manner. 26 In addition, its antitumor activity in vitro has been shown to be potentiated by combination with EGFR tyrosine kinase inhibitors such as gefitinib. 27 In our study, treatment with vandetanib monotherapy significantly inhibited tumor growth and increased survival in vivo. Vandetanib, given by oral gavage to nude mice with FaDu tongue tumors and SCC61 tongue tumors, reduced the tumor size by 42% and 53%, respectively, compared with control mice at endpoint. Vandetanib treatment also significantly increased survival when compared with control mice.
The vandetanib and paclitaxel combination prolonged survival, inhibited the tumor growth, induced apoptosis in tumor and endothelial cells, and suppressed MVD compared with the vandetanib group, indicating that adding paclitaxel confers additive growth inhibition by vandetanib. The combination treatment led to 75% decreases in the mean tumor volumes in both cell lines. In addition, our quantitative immunohistochemical analysis suggests that the combination treatment of vandetanib and paclitaxel had a greater effect on the induction of tumor cell apoptosis compared to each single treatment group. The angiogenic effect of vandetanib alone was evaluated by quantifying the MVD. We found that vandetanib significantly decreased MVD, which is consistent with the results of previous reports. 28, 29 In our study, paclitaxel decreased MVD slightly and induced slight but significant apoptosis in the endothelial cells. These data are consistent with those from previous studies, which indicated paclitaxel has antiangiogenic activity, 30, 31 and they suggest that the combined effect of paclitaxel and vandetanib might be greater on endothelial cells and tumor cell apoptosis than the effect of either agent alone.
Although the SCC61 cell line showed resistance against vandetanib from our MTT assay data and our apoptosis data in vitro compared to the FaDu cell line, we found no major differences in the in vivo antitumor effects of vandetanib between FaDu tumors and SCC61 tumors. This might be because the antitumor effects of vandetanib in HNSCC may result primarily from inhibiting VEGF signaling and, thus, represent indirect antitumor effects rather than direct antiproliferative effects on the tumor. These findings might reflect the biological differences between the 2 cell lines.
Although the difference was not statistically significant, the combination group had a much lower incidence of cervical lymph node metastases, with only 1 mouse having cervical lymph node metastasis. This finding is consistent with our previous report in which combined anti-EGFR and VEGFR-2 antibody targeted therapy using DC101 and cetuximab inhibited the growth of SCC of the oral tongue and also decreased the incidence of the neck lymph node metastases on orthotopic xenografts of metastatic SCC of the oral tongue. 32 As angiogenesis is thought to play an important role in tumor growth and metastasis 33 and the EGFR pathway is 1 of the major growth and survival signaling pathways in HNSCC, blocking these 2 pathways could be very helpful in the treatment of cervical nodal disease in patients with HNSCC.
Preclinical studies of vandetanib in gastric, pancreatic, prostate, and colon cancer orthotopic tumor models have shown findings that support our findings with regard to its potential antitumorigenic and survival-prolonging effects. 29, [34] [35] [36] Several papers have reported the impact of treatment of HNSCC with vandetanib 37, 38 ; however, this is the first report that assessed the effects of treatment with vandetanib alone and in combination with paclitaxel in an orthotopic mouse model of HNSCC. The oral bioavailability of vandetanib makes it more convenient for use than monoclonal antibodies. Based on successful preclinical results, clinical trials of vandetanib have advanced quickly and have shown promise. A recent clinical study reported that the combination treatment with vandetanib (100 mg) and docetaxel in patients with stage III or stage IV non-small cell lung cancer increased progression-free survival significantly compared to docetaxel treatment alone. 39 Clinical trials of vandetanib for HNSCC are also underway. A phase I study of vandetanib combined with radiation therapy in patients with previously untreated, unresected, stage III or stage IV HNSCC reported that 100 mg of vandetanib was the maximum tolerated dose with radiation therapy and cisplatin treatment. 40 Further clinical studies of vandetanib for HNSCC are needed.
In summary, we have corroborated previous reports of targeted in vitro EGFR and VEGFR-2 tyrosine kinase inhibition by vandetanib. 9 Our findings also demonstrate the preclinical efficacy of vandetanib, as a dual inhibitor of EGFR and VEGFR-2 signaling, in diminishing in vivo tumor growth and prolonging survival in mice with orthotopic human HNSCC xenografts. These favorable results support the evaluation of vandetanib in clinical trials, some of which have been initiated at our center, for patients with HNSCC.
